Loading company…
New York biotech using AI platforms for biomedical research, drug discovery and digital pathology.
Founded in 2016 in New York, US, Owkin, Inc. applies artificial intelligence to biomedical research, drug development and diagnostics. Its Owkin K platform integrates multimodal data for research teams, and it is developing OKN4395, a selective triple inhibitor in Phase 1 trials. It serves academic institutions and pharmaceutical companies, mainly in North America and Europe, and has raised EUR 33.00 mn across 9 deals, most recently in March 2023 from Bpifrance Investissement; the stage is Series A.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in